论文部分内容阅读
分析23例双原发癌患者在患第Ⅰ、Ⅱ原发癌后的T细胞亚群、皮肤超敏试验结果，显示：（1）双原发癌患者生存期与两癌发生间隔时间及治疗方式有关，间隔时间长和施根治性手术者，生存期长。（2）第Ⅰ、Ⅱ癌后CD4无明显变化，而CD8则升高，CD4／CD8均下降；第Ⅱ癌后的CD8及CD4／CD8较第Ⅰ癌后分别升高和下降，第Ⅱ癌后的皮肤超敏试验阳性率较第Ⅰ癌后明显下降。提示肿瘤患者的细胞免疫功能有所下降，且第Ⅱ癌后的细胞免疫功能下降较第Ⅰ癌后更加明显。
Analyze the T cell subsets and skin hypersensitivity test results of 23 patients with dual primary cancer after suffering from primary cancers I and II. The results showed that: (1) The survival time of dual primary cancer patients and the interval between two cancers and treatment With regard to the method, the long interval time and radical surgery, long survival time. (2) There was no significant change in CD4 after I and II cancers, but CD8 increased and CD4/CD8 decreased. After the second cancer, CD8 and CD4/CD8 were increased and decreased after the first cancer, respectively. The positive rate of skin hypersensitivity after the test was significantly lower than that of the first cancer. It suggests that the cellular immune function of cancer patients has declined, and the decline of cellular immune function after the second cancer is more obvious than after the first cancer.